Search clinical trials for: Cisplatin and Gemcitabine

Total 270532 results

Gyeongsang National University Hospital
Samsung Medical Center; Dong-A University; Chung-Ang University

Terminated

Randomized Trial of Gemcitabine/Cisplatin Versus S-1/Cisplatin in Advanced Biliary Cancer

Metastatic Biliary Tract Cancer | Locally Advanced Biliary Tract Cancer

Korea, Republic of
3D Medicines (Sichuan) Co., Ltd.

Not yet recruiting

Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers

Biliary Tract Neoplasms
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Guangdong Provincial People... and other collaborators

Active, not recruiting

GP vs PF as Induction Chemotherapy Combined With CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Nasopharyngeal Neoplasms | Nasopharyngeal Diseases | Head and Neck Neoplasm

China
Kansai Hepatobiliary Oncology Group

Completed

GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer

Biliary Tract Cancer

Japan
SUNHO（China）BioPharmaceutical CO., Ltd.

Recruiting

IAH0968 in Combination With GC for the Treatment of HER2-Positive Unresectable Advanced/Metastatic Malignant Tumors

HER2 Gene Mutation

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

An Phase III Study, Multicenter，Randomized Controlled Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Bladder Cancer

China
Institut du Cancer de Montpellier - Val d'Aurelle

Active, not recruiting

A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for Muscle-infiltrative Bladder Cancer (GETUGV04)

Infiltrating Bladder Urothelial Carcinoma

France
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Tongji Hospital; Hunan Cancer... and other collaborators

Recruiting

Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Unknown

GC Regimen Chemotherapy Plus CIK Cells for Metastatic Nasopharyngeal Carcinoma

Stage IV Nasopharyngeal Carcinoma

China
Barmherzige Brüder Vienna

Completed

Neoadjuvant Chemotherapy in Locally Advanced Bladder Cancer

Bladder Cancer

Austria
Akeso

Recruiting

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China, United States, Australia, Brazil, Canada
Second Affiliated Hospital, School of Medicine,...
The First Affiliated Hospital of Zhengzhou University; The Affiliated Tumor...

Recruiting

Lenvatinib, Tislelizumab Combined With Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma

Advanced Cholangiocarcinoma

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients With Advanced Cholangiocarcinoma

Advanced Cholangiocarcinoma

China
Hua Li

Recruiting

Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma

Unresectable Intrahepatic Cholangiocarcinoma

China
Kansai Hepatobiliary Oncology Group

Completed

Oral Rehydration Therapy for Short Hydration in Chemotherapy With CDDP Plus GEM for Biliary Tract Cancer

Biliary Tract Cancer

Japan
AstraZeneca

Recruiting

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (TOURMALINE)

Biliary Tract Cancer

France, Spain, Italy, Korea, Republic of, Japan, Germany, United States, Singapore
Hannover Medical School

Completed

PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine) (PiCCA)

Cholangiocarcinomas

Germany
Sun Yat-sen University
Peking University; Zhejiang Cancer Hospital; Fudan University; West China Hospital and other collaborators

Unknown

Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
First People's Hospital of Foshan

Unknown

Study of Neoadjuvant Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
University College, London
Eli Lilly and Company

Completed

Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors (ABC-02)

Gallbladder Cancer | Extrahepatic Bile Duct Cancer

United Kingdom
Tata Memorial Centre

Recruiting

Radiation Therapy in Unresectable Gall Bladder Cancer (RUGB)

Gall Bladder Cancer

India
Chaosu Hu
Zhejiang Cancer Hospital; Fujian Cancer Hospital; Affiliated Hospital of Jiangnan... and other collaborators

Recruiting

Sequential or Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced NPC

Nasopharyngeal Carcinoma

China
Spanish Lung Cancer Group

Terminated

Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma (BREC)

Non Small Cell Lung Cancer | BRCA1 Mutation

Spain
Kansai Hepatobiliary Oncology Group

Completed

A Phase I Study of Adjuvant Chemotherapy With GC in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy

Biliary Tract Cancer

Japan
The European Uro-Oncology Group
Centre for Human Drug Research, Netherlands

Recruiting

Feasibility of Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (URANUS)

Upper Tract Urothelial Carcinoma

Norway, Spain, Netherlands
Kuwait Cancer Control Center

Recruiting

Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Kuwait
Shantou University Medical College

Unknown

Cisplatin for Malignant Pleural Effusion in Patients With Non-small-cell Lung Cancer

Pleural Effusion, Malignant

China
BeiGene

Active, not recruiting

Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer

Recurrent or Metastatic Nasopharyngeal Cancer

China, Taiwan, Thailand
Sierra Oncology LLC - a GSK company

Completed

A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects

Advanced Solid Tumors

Spain, United Kingdom
Sirtex Medical

Completed

SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma (SIRCCA)

Intrahepatic Cholangiocarcinoma

France, United Kingdom, Belgium, Australia, Spain, United States, Italy, Netherlands
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Active, not recruiting

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Recurrent or Metastatic

China
Yung NA
Queen Mary Hospital, Hong Kong; Pamela Youde Nethersole Eastern Hospital

Recruiting

Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: A Pilot Randomized Controlled Trial

Muscle-Invasive Bladder Carcinoma | Muscle Invasive Bladder Urothelial Carcinoma

Hong Kong
Kansai Hepatobiliary Oncology Group

Unknown

A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node Metastasis

Biliary Tract Cancer

Japan
Kansai Hepatobiliary Oncology Group

Completed

Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer

Biliary Tract Cancer

Japan
Chuangzhen Chen

Recruiting

Study of Neoadjuvant Chemotherapy Versus Definite Concurrent Chemoradiotherapy for Locally Advanced Bulk Cervical Cancer

Cervical Cancer | Neoadjuvant Chemotherapy

China
UNICANCER

Completed

Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid Tumors (PACIFIK)

Metastatic Cancer | Solid Tumors

France
Sun Yat-sen University

Recruiting

Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC

Nasopharyngeal Carcinoma | Circulating Tumor Cell | Effects of Chemotherapy | Distant Metastases.Clinical

China
National University Hospital, Singapore

Completed

Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)

Nasopharyngeal Carcinoma

Singapore
Lahey Clinic

Withdrawn

Study of Sorafenib, Gemcitabine, and Cisplatin in Advanced Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

United States
Memorial Sloan Kettering Cancer Center
Mayo Clinic; Hartford Hospital

Active, not recruiting

Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

United States
Sun Yat-sen University

Unknown

Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms

China
Fudan University

Unknown

Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC) (GEP)

Breast Cancer

China
PCI Biotech AS

Completed

A Phase I/II Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas

Cholangiocarcinoma

Germany, France, Norway, United Kingdom
Zhejiang Cancer Hospital

Unknown

Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer

Biliary Tract Cancer

China
Sidney Kimmel Comprehensive Cancer Center at Johns...

Terminated

A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC. (NA_00067809)

Non-small Cell Lung Cancer Metastatic

United States
Shenzhen Hornetcorn Bio-technology Company, LTD

Unknown

Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients

NSCLC

China
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery

Bladder Cancer

United States, Canada
EpicentRx, Inc.

Terminated

RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy (EPIC)

Cholangiocarcinoma

United States
Sanofi

Completed

ADVANCED Phase II Trial of Weekly vs 3 Weekly Docetaxel and Cisplatin Followed by Gemcitabine in Non-small-cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Italy
National Cancer Center, Korea

Completed

Pharmacogenomic Study for Providing Personalized Strategy to the Treatment of Non-small Cell Lung Cancer (NSCLC) IIIB/IV

Non Small Cell Lung Cancer

Korea, Republic of

3

Subscribe